TC
CPXX

TFS Capital’s CELATOR PHARMACEUTICALS INC. COMMON STOCK CPXX Stock Holding History

TFS Capital’s Portfolio CPXX Stock Details CPXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-19,406
Closed -$34K – 1208
2015
Q4 		$34K Sell
19,406
-3,037
-14% -$5.21K ﹤0.01% 718
2015
Q3 		$37K Buy
22,443
+2,064
+10% +$4.58K ﹤0.01% 858
2015
Q2 		$46K Buy
+20,379
New +$46.2K ﹤0.01% 859

Other funds holding CPXX

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TFS Capital's CPXX Position: Q1 2016 in Review

TFS Capital sold out of CELATOR PHARMACEUTICALS INC. COMMON STOCK (CPXX) in Q1 2016, closing a stake of 19,406 shares — an estimated $34K sold.

TFS Capital first reported a position in CPXX in Q2 2015 and held it in 3 quarters. The position peaked at $46K in Q2 2015. 58 funds tracked by Wall St. Rank hold CPXX as of Q1 2016.

  • TFS Capital reported no remaining CELATOR PHARMACEUTICALS INC. COMMON STOCK position as of Q1 2016 after selling out during the quarter.
  • TFS Capital sold 19,406 CELATOR PHARMACEUTICALS INC. COMMON STOCK shares in Q1 2016, an estimated $34K.
  • TFS Capital first reported a position in CELATOR PHARMACEUTICALS INC. COMMON STOCK in Q2 2015 and held it in 3 quarters.
  • TFS Capital's CELATOR PHARMACEUTICALS INC. COMMON STOCK position peaked at $46K in Q2 2015.
  • 58 funds tracked by Wall St. Rank held CELATOR PHARMACEUTICALS INC. COMMON STOCK as of Q1 2016.

Based on TFS Capital's 13F filing for Q1 2016, filed 10 May 2016.